Acquired by Alcon in Nov 2022
Company logo

AERI - Aerie Pharmaceuticals, Inc.

NASDAQ -> Healthcare -> Drug Manufacturers—Specialty & Generic
Durham, United States
Type: Equity

AERI price evolution
AERI
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Current assets
Cash $54.09 $39.44 $56.44 $37.19
Short term investments $118.37 $144.93 $138.81 $102.61
Net receivables $73.88 $68.08 $63.62 $158.83
Inventory $46.76 $47.01 $40.19 $40.41
Total current assets $302.81 $311.41 $316.97 $355.65
Long term investments $3.98
Property, plant & equipment $71.06 $72.39 $73.14 $74.14
Goodwill & intangible assets
Total noncurrent assets $72.78 $73.93 $78.58 $75.74
Total investments $118.37 $144.93 $142.79 $102.61
Total assets $375.59 $385.34 $395.55 $431.39
Current liabilities
Accounts payable $9.06 $9.28 $7.88 $8.29
Deferred revenue $70.88 $70.44 $70 $64.31
Short long term debt $4.87 $4.74 $4.46 $4.37
Total current liabilities $133.33 $119.66 $115.29 $124.99
Long term debt $332.11 $332.55 $332.71 $256.28
Total noncurrent liabilities $406.24 $406.81 $405.97 $323.73
Total debt $336.99 $337.29 $337.18 $260.64
Total liabilities $539.57 $526.47 $521.26 $448.72
Shareholders' equity
Retained earnings -$1188.04 -$1161.21 -$1141.84 -$1153.91
Other shareholder equity -$0.8 -$0.79 -$0.43 -$0.13
Total shareholder equity -$163.98 -$141.13 -$125.71 -$17.33
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Current assets
Cash $37.19 $151.57 $143.94 $202.82
Short term investments $102.61 $88.79 $165.25
Net receivables $158.83 $56.02 $38.35 $2.71
Inventory $40.41 $27.06 $21.05 $10.11
Total current assets $355.65 $331.75 $376.34 $220.18
Long term investments
Property, plant & equipment $74.14 $68.34 $74.67 $60.52
Goodwill & intangible assets
Total noncurrent assets $75.74 $70.29 $76.27 $64.87
Total investments $102.61 $88.79 $165.25
Total assets $431.39 $402.05 $452.61 $285.04
Current liabilities
Accounts payable $8.29 $8.83 $12.77 $12.4
Deferred revenue $64.31 $50.86
Short long term debt $4.37 $4.92 $5.5
Total current liabilities $124.99 $104.47 $83.65 $50.78
Long term debt $256.28 $220.58 $200.75
Total noncurrent liabilities $323.73 $273.61 $202.01 $6.45
Total debt $260.64 $225.5 $206.25
Total liabilities $448.72 $378.08 $285.66 $57.24
Shareholders' equity
Retained earnings -$1153.91 -$1079.1 -$896 -$696.42
Other shareholder equity -$0.13 -$0.05 -$0.09
Total shareholder equity -$17.33 $23.97 $166.95 $227.81
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Revenue
Total revenue $36.13 $33.31 $29.84 $114.67
Cost of revenue $6.93 $3.74 $6.78 $6.07
Gross Profit $29.2 $29.57 $23.05 $108.6
Operating activities
Research & development $21.99 $19.56 $25.17 $20.85
Selling, general & administrative $33.88 $28.15 $31.52 $36.01
Total operating expenses $55.87 $47.71 $56.7 $56.86
Operating income -$26.67 -$18.14 -$33.64 $51.74
Income from continuing operations
EBIT -$26.73 -$19.32 -$35.2 $46.02
Income tax expense $0.1 $0.05 $0.69 $0.49
Interest expense
Net income
Net income -$26.83 -$19.37 -$35.89 $45.53
Income (for common shares) -$26.83 -$19.37 -$35.89 $45.53
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Revenue
Total revenue $194.13 $83.14 $69.89 $24.18
Cost of revenue $26.85 $25.33 $4.83 $0.64
Gross Profit $167.29 $57.8 $65.06 $23.54
Operating activities
Research & development $75.84 $74.01 $91.38 $86.12
Selling, general & administrative $137.81 $137.18 $138.4 $120.61
Total operating expenses $213.64 $213.5 $252.55 $233.28
Operating income -$46.35 -$155.69 -$187.49 -$209.74
Income from continuing operations
EBIT -$74.22 -$177.86 -$199.67 -$232.57
Income tax expense $0.59 $5.25 -$0.09 $0
Interest expense
Net income
Net income -$74.81 -$183.1 -$199.58 -$232.57
Income (for common shares) -$74.81 -$183.1 -$199.58 -$232.57
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Net income -$26.83 -$19.37 -$35.89 $45.53
Operating activities
Depreciation $3.35 $3.42 $3.61 $9.78
Business acquisitions & disposals
Stock-based compensation $3.64 $3.96 $4.63 $6.17
Total cash flows from operations -$11.4 -$13.23 $61.91 -$30.11
Investing activities
Capital expenditures -$0.81 -$1.37 -$1.6 -$0.75
Investments $26.68 -$2.56 -$40.7 $2.81
Total cash flows from investing $25.86 -$3.93 -$42.3 $2.06
Financing activities
Dividends paid
Sale and purchase of stock $0.19 $0.17 -$0.36 $3.39
Net borrowings
Total cash flows from financing $0.19 $0.17 -$0.36 $3.39
Effect of exchange rate
Change in cash and equivalents $14.65 -$17 $19.25 -$24.66
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net income -$74.81 -$183.1 -$199.58 -$232.57
Operating activities
Depreciation $37.5 $34.16 $18.11 $2.44
Business acquisitions & disposals -$7.83
Stock-based compensation $29.52 $40.09 $45.09 $38.73
Total cash flows from operations -$99.15 -$64.69 -$150.43 -$152.58
Investing activities
Capital expenditures -$3.29 -$3.1 -$9.96 -$31.31
Investments -$14.91 $76.28 -$165.45 $52.1
Total cash flows from investing -$18.2 $73.18 -$183.25 $20.79
Financing activities
Dividends paid
Sale and purchase of stock $2.97 $0.76 $135.97
Net borrowings $308.35 -$1.88
Total cash flows from financing $2.97 -$0.86 $274.8 $137.04
Effect of exchange rate
Change in cash and equivalents -$114.38 $7.63 -$58.88 $5.25
Fundamentals
Market cap N/A
Enterprise value N/A
Shares outstanding 49.39M
Revenue $213.94M
EBITDA -$15.07M
EBIT -$35.23M
Net Income -$36.55M
Revenue Q/Q 23.25%
Revenue Y/Y 105.41%
P/E ratio 0.00
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio 0.00
Book/Share -3.30
Cash/Share 1.10
EPS -$0.74
ROA -9.21%
ROE 32.63%
Debt/Equity -25.89
Net debt/EBITDA -32.22
Current ratio 2.27
Quick ratio 1.92